Your browser is no longer supported. Please, upgrade your browser.
Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.43 Insider Own0.50% Shs Outstand180.61M Perf Week-3.42%
Market Cap14.73B Forward P/E367.25 EPS next Y0.22 Insider Trans-17.82% Shs Float175.23M Perf Month1.53%
Income-74.70M PEG- EPS next Q-0.18 Inst Own- Short Float6.43% Perf Quarter-10.69%
Sales1.31B P/S11.21 EPS this Y88.70% Inst Trans0.18% Short Ratio8.39 Perf Half Y-5.70%
Book/sh16.00 P/B5.10 EPS next Y133.30% ROA-2.70% Target Price114.30 Perf Year-13.44%
Cash/sh7.73 P/C10.55 EPS next 5Y63.92% ROE-4.20% 52W Range75.81 - 100.51 Perf YTD-8.57%
Dividend- P/FCF- EPS past 5Y14.70% ROI-1.30% 52W High-18.88% Beta1.68
Dividend %- Quick Ratio2.10 Sales past 5Y21.30% Gross Margin81.60% 52W Low7.55% ATR2.54
Employees2581 Current Ratio2.70 Sales Q/Q19.40% Oper. Margin-1.10% RSI (14)49.14 Volatility2.98% 3.20%
OptionableYes Debt/Eq0.42 EPS Q/Q88.70% Profit Margin-8.90% Rel Volume0.93 Prev Close81.13
ShortableYes LT Debt/Eq0.29 EarningsApr 25 AMC Payout- Avg Volume1.34M Price81.53
Recom1.80 SMA201.06% SMA50-0.71% SMA200-5.70% Volume1,250,290 Change0.49%
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Aug-05-16Reiterated Stifel Buy $107 → $113
Aug-05-16Reiterated Piper Jaffray Overweight $107 → $120
Mar-08-16Upgrade Robert W. Baird Neutral → Outperform $110
Mar-03-16Reiterated Stifel Buy $105 → $107
Feb-29-16Reiterated Wedbush Neutral $117 → $105
Feb-26-16Reiterated RBC Capital Mkts Outperform $155 → $125
Feb-16-16Upgrade Stifel Hold → Buy $105
Apr-25-18 04:36PM  BioMarin: 1Q Earnings Snapshot Associated Press
04:05PM  BioMarin Announces First Quarter 2018 Financial Results PR Newswire
01:25PM  3 Charts That Suggest Biotech Stocks Are Headed Lower Investopedia
12:00PM  BioMarin Pharmaceutical Inc. to Host Earnings Call ACCESSWIRE
11:06AM  How Financially Strong Is BioMarin Pharmaceutical Inc (NASDAQ:BMRN)? Simply Wall St.
Apr-24-18 02:30PM  New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease PR Newswire
10:49AM  Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure Benzinga
10:09AM  What's in the Cards for BioMarin (BMRN) in Q1 Earnings? Zacks
Apr-20-18 02:00PM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-18-18 08:30AM  BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET PR Newswire
Apr-16-18 08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 10:06AM  Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus Zacks
09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
08:30AM  Todays Research Reports on Trending Tickers: Array BioPharma and BioMarin Pharmaceutical ACCESSWIRE
08:07AM  Did BioMarin Pharmaceutical Incs (NASDAQ:BMRN) Earnings Growth Outperform The Industry? Simply Wall St.
Apr-11-18 06:00AM  10 Cheap, High-Quality Stocks With Major Growth Catalysts Morningstar
Apr-10-18 04:23PM  How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal Investor's Business Daily
Apr-05-18 03:36PM  Catalyst (CPRX) Up on New Drug Application for Firdapse Zacks
Apr-03-18 03:48PM  Motley Fool 100 Update: What's In and What's Out Motley Fool
Apr-02-18 10:52AM  MARKETS: Why April could be a bad month for stocks Yahoo Finance Video
Mar-29-18 04:30PM  Roche Hashes Out Details Of Patient Deaths In Hemophilia Drug Investor's Business Daily
09:54AM  BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod Zacks
Mar-28-18 04:05PM  European Medicines Agency (EMA) Accepts BioMarin's Marketing Application for Pegvaliase MAA for Treatment of Phenylketonuria (PKU) PR Newswire
Mar-26-18 01:22AM  BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound? Zacks
Mar-23-18 05:58PM  BioMarin Pharmaceutical Incs (NASDAQ:BMRN) Path To Profitability Simply Wall St.
Mar-21-18 08:35AM  BioMarin's Gene Therapy Manufacturing Facility Recognized with Industry Award PR Newswire
Mar-07-18 06:00AM  10 Growth Stocks at Value Prices Morningstar
Mar-06-18 08:30AM  BioMarin to Attend Upcoming Investor Conference PR Newswire
Mar-01-18 11:51AM  Edited Transcript of BMRN earnings conference call or presentation 22-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-18 08:30AM  Rare Disease Day 2018: BioMarin Launches RARE Scholars Scholarship Program PR Newswire
07:00AM  Productive Pipeline Positions BioMarin for Success Morningstar
Feb-27-18 07:20AM  Blog Exposure - CHMP Recommended Against Approval of Puma Biotech's Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast Cancer ACCESSWIRE
Feb-26-18 09:48PM  Biomarin Pharmaceutical Inc (BMRN) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
04:25PM  BioMarin Turns a Profit (on an Adjusted Basis) Motley Fool
Feb-23-18 04:45PM  Is This Biotech Hedging Its 2018 Outlook On A Key FDA Approval? Investor's Business Daily
11:52AM  Why Leerink Adjusted Upside Expectations For 3 Biotechs Benzinga
09:12AM  BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat Zacks
Feb-22-18 04:32PM  BioMarin reports 4Q loss Associated Press
04:05PM  BioMarin Announces Fourth Quarter and Full Year 2017 Financial Results PR Newswire
12:10PM  BioMarin Pharmaceutical Inc. to Host Earnings Call ACCESSWIRE
10:10AM  Biomarin Pharmaceutical Q4 Earnings Outlook Benzinga
Feb-20-18 09:40AM  What to Expect From BioMarin (BMRN) This Earnings Season? Zacks
Feb-19-18 10:50AM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-08-18 08:10AM  Consolidated Research: 2018 Summary Expectations for Meritor, Bloomin' Brands, Snap-On, Northern Trust, Quanta Services, and BioMarin Pharmaceutical Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-07-18 12:15PM  BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at WORLDSymposium 2018 PR Newswire
Feb-06-18 08:30AM  WORLDSymposium Recognizes BioMarin's Brineura® (cerliponase alfa) with 2018 New Treatment Award PR Newswire
Feb-05-18 04:05PM  BioMarin Announces 20 Presentations at 14th Annual WORLDSymposium 2018 PR Newswire
06:22AM  5 Top Stocks With 100% Buy Ratings Right Now TheStreet.com
Jan-26-18 10:30AM  5 Biotechs That May Surge On Takeovers Investopedia
Jan-24-18 05:34PM  5 biotech buyout candidates you should look at right now MarketWatch
01:31PM  Clovis, Incyte And BioMarin Are Todd Hagopian's Top Takeover Candidates Forbes
09:00AM  Will Sanofi's Big Hemophilia Deal Pay Off? Motley Fool
08:30AM  BioMarin to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast on Thursday, February 22 at 4:30pm ET PR Newswire
Jan-12-18 08:04AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Jan-11-18 09:03AM  How Akcea Therapeutics Volanesorsen Performed in 3Q17 Market Realist
07:34AM  How Ioniss Spinraza Performed in 3Q17 Market Realist
Jan-10-18 05:40PM  A Look at Ioniss 3Q17 Revenue Stream Market Realist
10:33AM  Analysts Recommendations for Incyte in January 2018 Market Realist
Jan-09-18 11:55AM  How Was Incytes Revenue Stream in 3Q17? Market Realist
08:03AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Jan-08-18 04:45PM  BioMarin's chief calls hemophilia treatment results 'extremely encouraging' CNBC
03:00PM  Full interview with Shire CEO Flemming Ørnskov CNBC Videos
02:00PM  BioMarin CEO on hemophilia treatment success CNBC Videos
01:19PM  How To Trade The JPMorgan Healthcare Conference Benzinga
Jan-06-18 10:30AM  Why This Gene Therapy Pioneer Crashed 29.8% in December Motley Fool
Jan-05-18 09:00AM  Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN) Zacks
Jan-03-18 08:30AM  BioMarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Jan-02-18 02:45PM  Piper Jaffray analyst: What to expect from biotech in 201... CNBC Videos
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
Dec-27-17 07:04AM  Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo Zacks
Dec-26-17 09:17AM  BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA Zacks
Dec-22-17 08:30AM  BioMarin Receives Anticipated Notification of PDUFA Extension for Pegvaliase Biologics License Application (BLA) to May 28, 2018 PR Newswire
Dec-20-17 09:48AM  BioMarin's (BMRN) Gene Therapy Enters First Phase III Study Zacks
Dec-19-17 04:05PM  BioMarin Doses First Patient in Global GENEr8-1 Phase 3 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A PR Newswire
03:11PM  New Gene Therapies Could Change Hemophilia Forever Motley Fool
Dec-14-17 07:09PM  ASH 2017 Recap: These Were the Big Winners and Losers Motley Fool
03:26PM  Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform Benzinga
Dec-13-17 02:24PM  BioMarin Pharmaceutical, Inc. Value Analysis (NASDAQ:BMRN) : December 13, 2017 Capital Cube
12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
08:02AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:31AM  5 Biotech Buyout Candidates for 2018 Motley Fool
Dec-12-17 03:30PM  3 Reasons Spark Therapeutics Is a Buy After Its Crash Motley Fool
12:31PM  Spark Therapeutics: This Looks Bad Barrons.com
10:32AM  Analysts Recommendations for BioMarin in December 2017 Market Realist
10:15AM  Spark Therapeutics Stock Plunges on Hemophilia Therapy Data Zacks
09:03AM  How Did BioMarin Pharmaceuticals Drugs Perform in 3Q17? Market Realist
08:52AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5% Zacks
08:08AM  See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc. Markit
07:34AM  How BioMarin Performed in 3Q17 Market Realist
07:24AM  BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : December 12, 2017 Capital Cube
Dec-11-17 06:04PM  Why Biotech Stocks Are Just Too Darn Scary! Spark Tumbles 35% Barrons.com +7.46%
05:08PM  What Happened in the Stock Market Today Motley Fool
04:24PM  11 Biotech Stocks Moving From ASH 2017 Benzinga
03:30PM  Bluebird Bio rallies, Spark Therapeutics craters after unveiling data at ASH meeting MarketWatch
01:45PM  Spark Therapeutics' gene therapy program brings stock dow... CNBC Videos
12:43PM  Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today Motley Fool
12:09PM  Why BioMarin Pharmaceutical Inc. Stock Is Surging Today InvestorPlace
11:27AM  Biotech winners and losers: ASH Hematology Conference CNBC Videos
10:00AM  BioMarin Highlights New Results for Gene Therapy Valoctocogene Roxaparvovec at the 2017 American Society of Hemophilia (ASH) Meeting PR Newswire
09:39AM  Spark Therapeutics shares slide more than 40% after hemophilia data disappoint MarketWatch
BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerApr 24Option Exercise38.5910,000385,900300,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 24Sale82.2910,000822,887290,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Option Exercise38.5910,000385,900300,031Apr 25 08:30 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerApr 23Sale82.1511,059908,49762,543Apr 25 08:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Sale82.5810,000825,811290,031Apr 25 08:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 20Option Exercise38.5910,000385,900300,031Apr 24 07:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 20Sale83.6510,000836,458290,031Apr 24 07:50 PM
LAWLIS V BRYANDirectorApr 17Option Exercise38.593,750144,71318,610Apr 19 07:19 PM
LAWLIS V BRYANDirectorApr 17Sale85.003,750318,75014,860Apr 19 07:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.391,00014,390290,031Apr 09 03:51 PM
FUCHS HENRY JPresident, Worldwide R&DApr 02Option Exercise33.7910,000337,851163,326Apr 03 08:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 02Option Exercise14.391,00014,390289,031Apr 03 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 02Sale80.122,119169,77452,914Apr 03 09:00 PM
FUCHS HENRY JPresident, Worldwide R&DApr 02Sale80.1210,000801,200156,676Apr 03 08:51 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 29Sale79.691,537122,48455,033Mar 30 08:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise16.132,00032,250288,031Mar 30 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 27Option Exercise14.391,00014,390286,031Mar 28 06:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 26Option Exercise14.391,00014,390285,031Mar 28 06:36 PM
Davis George EricEVP, General CounselMar 23Sale81.353,350272,52387,989Mar 27 06:17 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 22Option Exercise14.391,00014,390297,106Mar 26 07:27 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 21Sale83.904,368366,47560,153Mar 23 04:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Option Exercise38.5915,000578,850311,106Mar 20 07:46 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 16Sale83.2615,0001,248,854296,106Mar 20 07:46 PM
Davis George EricEVP, General CounselMar 16Sale83.883,818320,25494,634Mar 20 07:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise38.5915,000578,850279,674Mar 20 02:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale84.7315,0001,270,901264,674Mar 20 02:16 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 09Sale82.392,972244,86355,332Mar 13 08:31 PM
Davis George EricEVP, General CounselMar 05Sale79.042,105166,37990,089Mar 07 06:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise14.391,00014,390273,216Mar 06 08:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 15Option Exercise38.5910,000385,900236,494Feb 20 08:40 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 15Sale84.6310,000846,285226,494Feb 20 08:40 PM
Davis George EricEVP, General CounselFeb 01Option Exercise38.5930,0001,157,700112,942Feb 05 08:13 PM
Davis George EricEVP, General CounselFeb 01Sale90.6630,0002,719,66582,942Feb 05 08:13 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 05Option Exercise38.5910,000385,900235,894Jan 09 08:36 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 05Sale90.3210,000903,203225,894Jan 09 08:36 PM
FUCHS HENRY JPresident, Worldwide R&DJan 02Option Exercise33.8015,000507,050148,976Jan 04 07:26 PM
LAWLIS V BRYANDirectorJan 02Option Exercise38.593,750144,71318,610Jan 04 08:16 PM
LAWLIS V BRYANDirectorJan 02Sale88.843,750333,15014,860Jan 04 08:16 PM
FUCHS HENRY JPresident, Worldwide R&DJan 02Sale89.2315,0001,338,401133,976Jan 04 07:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Option Exercise38.5910,000385,900235,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale89.6110,000896,125225,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Option Exercise38.5910,000385,900235,894Jan 02 05:29 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale89.8910,000898,912225,894Jan 02 05:29 PM
HERON ELAINE JDirectorDec 14Sale88.9080071,11638,385Dec 18 08:56 PM
Davis George EricEVP, General CounselNov 30Sale85.641,200102,76782,942Dec 04 08:26 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.062,915268,35528,761Oct 02 09:07 PM
BAFFI ROBERTEVP, Technical OperationsSep 28Sale92.5015,5001,433,676129,083Oct 02 09:07 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Option Exercise37.463,521131,89750,110Sep 26 07:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerSep 22Sale95.003,521334,49547,944Sep 26 07:19 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Option Exercise33.8015,000507,050151,422Sep 19 03:17 PM
LAWLIS V BRYANDirectorSep 15Option Exercise38.593,750144,71319,660Sep 19 03:27 PM
LAWLIS V BRYANDirectorSep 15Sale91.263,750342,22515,910Sep 19 03:27 PM
FUCHS HENRY JPresident, Worldwide R&DSep 15Sale90.5015,0001,357,500136,422Sep 19 03:17 PM
Davis George EricEVP, General CounselJun 23Option Exercise38.599,844379,88093,425Jun 27 08:46 PM
Davis George EricEVP, General CounselJun 23Sale96.609,844950,93083,581Jun 27 08:46 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise21.512,67157,45315,556Jun 23 05:39 PM
Mueller BrianSVP, Corporate ControllerJun 22Sale100.002,671267,10012,885Jun 23 05:39 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Option Exercise37.4660322,588137,025Jun 20 06:33 PM
FUCHS HENRY JPresident, Worldwide R&DJun 19Sale90.0060354,270136,422Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Option Exercise38.593,750144,71319,660Jun 20 06:31 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Option Exercise33.6514,397484,462150,819Jun 20 06:33 PM
FUCHS HENRY JPresident, Worldwide R&DJun 16Sale90.0014,3971,295,730136,422Jun 20 06:33 PM
LAWLIS V BRYANDirectorJun 16Sale90.003,750337,50015,910Jun 20 06:31 PM
Davis George EricEVP, General CounselJun 09Option Exercise23.549,239217,53083,581Jun 13 08:56 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 07Sale89.611,00489,96847,944Jun 09 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Option Exercise17.335,00086,650231,924Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 05Sale90.565,000452,800226,924Jun 06 08:34 PM
Davis George EricEVP, General CounselJun 05Sale91.049,471862,23074,342Jun 07 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Option Exercise17.335,00086,650238,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 02Sale89.705,000448,500233,564Jun 06 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Option Exercise17.335,00086,650238,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 01Sale87.535,000437,650233,564Jun 05 07:05 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Option Exercise17.337,423128,641240,987Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 31Sale88.297,423655,377233,564Jun 02 05:52 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Option Exercise17.335,00086,650238,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 24Sale88.385,000441,900233,564May 26 05:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Option Exercise17.335,00086,650238,564May 19 10:33 AM
BIENAIME JEAN JACQUESChief Executive OfficerMay 17Sale91.735,000458,650233,564May 19 10:33 AM
Davis George EricEVP, General CounselMay 16Option Exercise14.391,14616,49185,301May 17 06:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Option Exercise17.335,00086,650243,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 12Sale89.235,000446,150238,496May 16 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise17.335,00086,650243,496May 09 01:19 PM
Mueller BrianSVP, Corporate ControllerMay 08Option Exercise21.512,60055,92616,068May 10 03:23 PM
Mueller BrianSVP, Corporate ControllerMay 08Sale91.877,482687,33413,468May 10 03:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale93.175,000465,850238,496May 09 01:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Option Exercise17.335,00086,650243,496May 09 01:19 PM
Davis George EricEVP, General CounselMay 05Option Exercise38.592,50096,47587,751May 09 01:21 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Option Exercise36.314,486162,87955,030May 09 01:23 PM
MEIER RICHARD ADirectorMay 05Option Exercise17.337,500129,97534,260May 09 01:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 05Sale99.004,486444,11451,532May 09 01:23 PM
Davis George EricEVP, General CounselMay 05Sale100.342,500250,85385,251May 09 01:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 05Sale99.005,000495,000238,496May 09 01:19 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMay 02Sale96.7430229,21551,532May 04 08:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Option Exercise17.335,00086,650243,194May 01 05:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 27Sale95.725,000478,600238,194May 01 05:39 PM